fbpx

Författare: johan@emergers.se

CRUNCHFISH: Rights issue to stay the course on extended timeline

Analys, Research

As discussed in our previous update, Crunchfish has now settled on a path forward for the company’s financing. On Friday after the...

Read More

GRANGEX: Emerging as Europe’s top DR concentrate developer

Analys, Research

With the dust settling after the acquisition of Sydvaranger and the updated DFS for Dannemora in Q2’24, the next steps for GRANGEX are...

Read More

MOTION DISPLAY: Strong gross margin driving another profitable quarter  

Analys, Research

MODI reported Q2’24 sales largely in line with last year, at SEK 7.4m compared to SEK 7.6m in Q2’23. The gross margin increased by 6ppt...

Read More

PROLIGHT: Pre-validation readout in Q4 sets stage for multicenter trial in 2025

Analys, Research

Supported by the latest troponin data generated from whole blood samples on the final commercial cartridge design, Prolight is now ready to...

Read More

NANEXA: NEX-22 Progress, Revaluation and Financing

Analys, Research

After initiating dosing of the first patient in June with Nanexa’s long-acting depot formulation of the GLP-1 analog liraglutide, NEX-22...

Read More

CRUNCHFISH: Three avenues to address the strained financing

Analys, Research

While the commercialization of Crunchfish’s solution for offline payments has shown a longer sales cycle than expected, the company...

Read More

Agtira AB: Big launch and a capital-light expansion in the cards

Analys, Research

In terms of financials, Q2 was largely a repeat of Q1, with one-off replanting and remediation costs from the Q1 disease affecting the...

Read More

GRANGEX: Updated DFS confirming viability to produce high-grade iron ore at Dannemora

Analys, Research

The announcement of the updated DFS for Dannemora showed, as expected, higher CAPEX and OPEX compared to the FS announced in December 2022,...

Read More

PROLIGHT: SEK 17m UK grant a welcome external validation

Analys, Research

Prolight’s report for Q1’24 did not reveal any particular surprises. The positive SEK 5.6m revision to the FY’23 result stemming from...

Read More

AGTIRA: Mixed start to pivotal 2024

Analys, Research

As announced already in February, capacity utilization and turnover in Q1 were weighed down by the plant disease in Härnösand, with a...

Read More

For new research on growth stocks, sign up to our newsletter